{
  "society": "NICE",
  "version": "ng49_2025_update",
  "publication_date": "2025-09-15",
  "title": "NICE NG49 2025 update: MASLD nomenclature and resmetirom appraisal pending",
  "status": "published",
  "recommendations": [
    {
      "recommendation_id": "NICE-2025-R01",
      "topic": "definition",
      "text_en": "NICE adopts MASLD nomenclature for new guidance; existing pathways preserved.",
      "text_kr_summary": "NICE MASLD 명명법 채택.",
      "strength": "strong",
      "evidence_grade": "B",
      "cite_pmids": ["37363821"],
      "related_nits": [],
      "related_drugs": [],
      "supersedes": []
    },
    {
      "recommendation_id": "NICE-2025-R02",
      "topic": "elf_test",
      "text_en": "ELF >= 10.51 indicates advanced fibrosis; refer to hepatology; consider repeat at 2 years if indeterminate.",
      "text_kr_summary": "ELF >=10.51 진행 섬유화; 2년 후 재검.",
      "strength": "strong",
      "evidence_grade": "B",
      "cite_pmids": ["27649089"],
      "related_nits": ["ELF"],
      "related_drugs": [],
      "supersedes": ["NICE-2024-R02"]
    },
    {
      "recommendation_id": "NICE-2025-R11",
      "topic": "resmetirom",
      "text_en": "Resmetirom under NICE technology appraisal; not currently funded by NHS pending decision.",
      "text_kr_summary": "레스메티롬 NICE 기술평가 진행 중; NHS 미급여.",
      "strength": "weak",
      "evidence_grade": "C",
      "cite_pmids": ["38324483"],
      "related_nits": [],
      "related_drugs": ["resmetirom"]
    }
  ]
}